Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Revance Therapeutics (RVNC) Prices Upsized 8M Share Offering at $25/sh
-
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
-
Revance Therapeutics (RVNC) to Offer $150M in Stock
-
Revance Announces Proposed Public Offering of Common Stock
-
Revance Therapeutic (RVNC) PT Raised to $65 at Cowen After Daxxify Approved
-
Revance to Participate in the Cowen 42nd Annual Health Care Conference
-
Revance to Participate in Upcoming Virtual Healthcare Conferences
-
Revance to Participate in the Cowen 40th Annual Health Care Conference
-
Pre-Open 12/04: (HQY) (CHK) (EXPE) Higher (RVNC) (IMMU) (ZS) Lower (more...)
-
Revance Therapeutics (RVNC) Prices 6.5M Share Offering at $17/Sh
-
Revance Announces Pricing of Public Offering of Common Stock
-
After-Hours Movers 12/03: (HQY) (GPRO) (MA) Higher; (RVNC) (RLMD) (RAPT) Lower (more...)
-
Revance Therapeutics (RVNC) to Offer Common Stock
-
Revance Announces Proposed Public Offering of Common Stock
-
Revance to Participate in Upcoming Investor Conferences
-
Revance Announces Closing of Public Offering of Common Stock
-
Revance Therapeutics (RVNC) Prices 5.88M Share Common Offering at $17/Sh
-
Revance Announces Pricing of Public Offering of Common Stock
-
Revance Therapeutics (RVNC) Announces Proposed Approx. $100M Common Share Offering
-
Revance Announces Proposed Public Offering of Common Stock
-
Cowen Expects Revance Therapeutics (RVNC) Weakness to Reverse, Reiterates $55 Price Target
-
Revance to Participate in Upcoming Investor Conferences
-
Revance Announces Closing of Public Offering of Common Stock
-
Revance Therapeutics (RVNC) Prices 5.34M Offering of Common Stock at $31/Share
-
Revance Announces Pricing of Public Offering of Common Stock
-
Revance Therapeutics (RVNC) Plans $175 Million Public Offering of Common Stock
-
Revance Announces Proposed Public Offering of Common Stock
-
Revance Therapeutic (RVNC): A 24-Week Neurotoxin Would Be Disruptive, KOL Survey Suggests - Cowen
-
Revance to Participate in Upcoming Investor Conferences
-
Revance to Participate in Upcoming Investor Conferences
-
Pre-Open Stock Movers 12/24: (PN) (GWPH) (SUNE) Higher; (RVNC) (CALM) (NSC) Lower (more...)
-
Revance Therapeutics Announces Closing of Public Offering of Common Stock
-
Revance Therapeutics (RVNC) Prices 3.25M Common Offering at $36/Share
-
Revance Therapeutics Announces Pricing of Public Offering of Common Stock
-
Revance Therapeutics (RVNC) Announces 3.25M Stock Offering
-
Revance Therapeutics Announces Proposed Public Offering of Common Stock
-
Fresh Off Generic Sale, Allergan (AGN) is Poised for Merger of Epic Proportions (AMGN) (ABBV)
-
Revance Therapeutics (RVNC) to Offer 3M Shares
-
Cowen Starts Revance Therapeutic (RVNC) at Outperform
-
Revance Therapeutics (RVNC) IPO Opens Sharply Higher, Continues to Gain
-
Revance Therapeutics, Inc. (RVNC) Files $86.25M IPO

